国际皮肤性病学杂志    2006 32 (2): 105-107   ISSN: 2096-5540  CN: 32-1880/R   沙利度胺治疗皮肤病的进展 陈浩, 孙建方 中国医学科学院、中国协和医科大学皮肤病研究所 南京 210042 收稿日期 2005-06-13  修回日期 null  网络版发布日期 null 参考文献  [1] Deng L,Ding W,Granstein RD.Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells.J Invest Dermatol,2003,121:1060-1065. [2] Turk BE,Jiang H,Liu JO.Binding of thalidomide to alphal -acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.Proc Natl Acad Sci U S A,1996,93:7552-7556. [3] Bohle AS,KalthoffH.Molecular mechanisms of tumor metastasis and angiogenesis.Langenbecks Arch Surg,1999,384:133-140. [4] Yasui K,Kobayashi N,Yamazaki T,et al.Thalidomide as an immunotherapeutic agent:the effects on neutrophil-mediated inflammation.Curr Pharm Des,2005,11:395-401. [5] Du GJ,Lin HH,Xu QT,et al.Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis.Vascul Pharmacol,2005,43:112-119. [6] Tadesse A,Shannon EJ.Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages.Clin Diagn Lab Immunol,2005,12:130-134. [7] Villahermosa LG,Fajardo TT Jr,Abalos RM,et al.A randomized,double-blind,double-dummy,controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum.Am J Trop Med Hyg,2005,72:518-526. [8] Cuadrado MJ,Karim Y,Sanna G,et al.Thalidomide for the treatment of resistant cutaneous lupus:efficacy and safety of different therapeutic regimens.Am J Med,2005,118:246-250. [9] Gambini D,Carrera C,Passoni E,et al.Thalidomide treatment for hypertrophic cutaneous lupus erythematosus.J Dermatolog Treat,2004,15:365-371. [10] Lu KQ,Brenneman S,Bums R Jr,et al.Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways.Photodermatol Photoimmunol Photomed,2003,19:272-280. [11] Cummins DL,Gaspari AA.Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus:discordant effects on minimal erythema dose and sunburn cell formation.Br J Dermatol,2004,151:458-464. [12] Nasca MR,O' Toole EA,Palicharla P,et al.Thalidomide increases human keratinocyte migration and proliferation.J Invest Dermatol,1999,113:720-724. [13] Hamuryudan V,Mat C,Saip S,et al.Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome.A randomized,double-blind,placebo-controlled trial.Ann Intern Med,1998,128:443-450. [14] Kari JA,Shah V,Dillon MJ.Behcet's disease in UK children:clinical features and treatment including thalidomide.Rheumatology (Oxford),2001,40:933-938. [15] Sayarlioglu M,Kotan MC,Topcu N,et al.Treatment of recurrent perforating intestinal ulcers with thalidomide in Behcet's disease.Ann Pharmacother,2004,38:808-811. [16] Revuz J,Guillaume JC,Janier M,et al.Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis.Arch Dermatol,1990,126:923-927. [17] Bonnetblanc JM,Royer C,Bedane C.Thalidomide and recurrent aphthous stomatitis:a follow-up study.Dermatology,1996,193:321-323. [18] Eisen D,Lynch DP.Selecting topical and systemic agents for recurrent aphthous stomatitis.Cutis,2001,68:201-206. [19] Paterson DL,Georghiou PR,Allworth AM,et al.Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection.Clin Infect Dis,1995,20:250-254. [20] Radomsky CL,Levine N.Thalidomide.Dermatol Clin,2001,19:87-103. [21] Settles B,Stevenson A,Wilson K,et al.Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide.Cell Mol' Biol(Noisy-le-grand),2001,47:1105-1114. [22] Browne PV,Weisdorf DJ,DeFor T,et al.Response to thalidomide therapy in refractory chronic graft-versus-host disease.Bone Marrow Transplantation.2000,26:865-869. [23] Kulkarni S,Powles R,Sirohi B,et al.Thalidomide after allogeneic haematopoietic stem cell transplantation:activity in chronic but not in acute graft-versus-host disease.Bone Marrow Transplant,2003,32:165-170. [24] Chao NJ,Parker PM,Niland JC,et al.Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.Biol Blood Marrow Transplant,1996,2:86-92. [25] Little RF,Wyvill KM,Pluda JM,et al.Activity of thalidomide in AIDS-related Kaposi's sarcoma.J Clin Oncol,2000,18:2593-2602. [26] Fife K,Howard MR,Gracie F,et al.Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre.Int J STD AIDS,1998,9:751-755. [27] Vacca A,Scavelli C,Montefusco V,et al.Thalidomide downregulares angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.J Clin Oncol,2005,23:5334-5346. 通讯作者: 孙建方,email:fangmin5758@yahoo.com.cn